Arcellx, Inc. (NASDAQ:ACLX – Get Free Report) has received a consensus rating of “Buy” from the twelve research firms that are currently covering the firm, Marketbeat reports. Twelve investment analysts have rated the stock with a buy recommendation. The average 1 year target price among analysts that have covered the stock in the last year is $53.31.
A number of brokerages recently commented on ACLX. Leerink Partnrs reaffirmed an “outperform” rating on shares of Arcellx in a research note on Thursday, October 12th. HC Wainwright lifted their price objective on Arcellx from $49.00 to $50.00 and gave the stock a “buy” rating in a research note on Tuesday, August 15th. TD Cowen assumed coverage on Arcellx in a research note on Monday, October 30th. They set an “outperform” rating for the company. Needham & Company LLC reissued a “buy” rating and issued a $51.00 target price on shares of Arcellx in a research note on Tuesday, August 15th. Finally, Robert W. Baird boosted their target price on Arcellx from $40.00 to $52.00 and gave the company an “outperform” rating in a research note on Tuesday, August 15th.
Institutional Trading of Arcellx
Arcellx Trading Up 1.5 %
ACLX stock opened at $45.30 on Tuesday. The company has a market cap of $2.19 billion, a P/E ratio of -11.44 and a beta of -0.57. Arcellx has a twelve month low of $18.70 and a twelve month high of $48.92. The company has a quick ratio of 3.57, a current ratio of 3.57 and a debt-to-equity ratio of 0.03. The business has a fifty day moving average of $35.22 and a 200-day moving average of $36.66.
Arcellx (NASDAQ:ACLX – Get Free Report) last announced its quarterly earnings data on Monday, August 14th. The company reported ($0.50) EPS for the quarter, topping analysts’ consensus estimates of ($0.68) by $0.18. The company had revenue of $14.30 million for the quarter, compared to analyst estimates of $82.38 million. As a group, equities research analysts expect that Arcellx will post -2.37 EPS for the current year.
Arcellx, Inc, a clinical-stage biotechnology company, engages in the development of various immunotherapies for patients with cancer and other incurable diseases. The company's lead ddCAR product candidate is CART-ddBCMA, which is in phase 2 clinical trial for the treatment of patients with relapsed or refractory (r/r) multiple myeloma (MM).
- Five stocks we like better than Arcellx
- How Investors Can Find the Best Cheap Dividend Stocks
- These 5 small-cap impact stocks are making social change
- How to Choose Top Rated Stocks
- Alphabet slays its earnings but falls on its sword with cloud
- Conference Calls and Individual Investors
- There’s nothing artificial about NVIDIA’s relationship with AI
Receive News & Ratings for Arcellx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Arcellx and related companies with MarketBeat.com's FREE daily email newsletter.